Loading
A phase 2 trial of Palbociclib, Cetuximab and Fulvestrant in head and neck squamous cell carcinoma, run by Pfizer, active and no longer recruiting.
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies is a phase 2 interventional study registered as NCT05226871 by Pfizer, with 35 participants enrolled, started 2022-07-07 and due to reach its primary completion in 2029-12-31. Interventions recorded: Palbociclib, Cetuximab, Fulvestrant and Letrozole.
Shares Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares Cetuximab, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Palbociclib, Fulvestrant, CDK4/6 inhibitors and the tag pipeline.
Shares Palbociclib, Fulvestrant and the tag pipeline.
Shares Fulvestrant, CDK4/6 inhibitors and the tag pipeline.